Amgen Inc. (AMGN) is a biopharmaceutical company focused on developing innovative medicines for serious illnesses with a market capitalization of $157.2 billion. While the stock has underperformed the S&P 500 over the past year, it has risen 12% year-to-date. However, setbacks in its obesity-drug pipeline and pricing pressures have dampened growth expectations. Analysts expect EPS to grow 6.3% in fiscal 2025. The consensus rating is a “Moderate Buy,” with a mean price target of $313.92, suggesting a potential 7.5% upside. Oppenheimer reaffirmed a Buy rating with a $380 price target, indicating a 30% upside.

Read more at Barchart: Amgen Stock: Analyst Estimates & Ratings